Finanzas de Sanara Medtech Inc (SMTI)SMTISanara Medtech Inc

Sanara MedTech Inc. (SMTI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Soft tissue repair products, accounting for 89.7% of total sales, equivalent to $24.94M. Another important revenue stream is Bone fusion products. Understanding this composition is critical for investors evaluating how SMTI navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Sanara MedTech Inc. maintains a gross margin of 90.76%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 10.29%, while the net margin is -1.46%. These profitability ratios, combined with a Return on Equity (ROE) of 23.72%, provide a clear picture of how effectively SMTI converts its operational activities into shareholder value.

In the context of the broader market, SMTI competes directly with industry leaders such as TMCI and ANIK. With a market capitalization of $297.11M, it holds a leading position in the sector. When comparing efficiency, SMTI's gross margin of 90.76% stands against TMCI's 78.47% and ANIK's 65.15%. Such benchmarking helps identify whether Sanara MedTech Inc. is trading at a premium or discount relative to its financial performance.

Sanara's gross margin is strong at 90.76%, indicating solid profitability on sales. However, the company has struggled with net income, posting a loss of $452,864 in Q2 2026, which raises concerns about its financial stability.